A double beat on earnings, plus positive adjustments to certain guidance items, lifted the company's shares.Adaptive Biotechnologies (ADPT 2.25%), a company that, in its own words, "aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease," was the cure for the stock market blahs on Wednesday. The commercial-stage biotech reported encouraging quarterly results, and investors signaled approval by trading the stock up by more than 2%. By contrast, the S ...

Investor Relations Presentation Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy ...

Adaptive Biotechnologies Corporation. (NASDAQ:ADPT) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Kyle Piskel - CFO Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandberg Tom Stevens - TD Cowen Operator Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2024 Earnings Call. Please note, ...

Adaptive Biotechnologies (ADPT) reported $41.87 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 11.2%. EPS of -$0.33 for the same period compares to -$0.40 a year ago.The reported revenue represents a surprise of -0.78% over the Zacks Consensus Estimate of $42.2 million. With the consensus EPS estimate being -$0.35, the EPS surprise was +5.71%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectatio ...

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.71%. A quarter ago, it was expected that this lifesciences research company would post a loss of $0.32 per share when it actually produced a loss of $0.30, delivering a surprise of 6.25%. Over the last four qua ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-090702 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction (IRS Employer of Incorporation) (Commission File Number) Identification No.) 1165 Eastlake Avenue East Seattle, Washington 98109 ...

Core Insights - Adaptive Biotechnologies Corporation has concluded its strategic review, deciding to operate its Minimal Residual Disease (MRD) and Immune Medicine businesses independently while maintaining a strong capital position to support both segments [2][4] Business Update - The company reported preliminary revenue for Q1 2024, estimating total revenue between $41 million and $43 million, reflecting a 12% increase compared to Q1 2023 [3] - MRD revenue is projected to be between $31 million and $32 million for Q1 2024, marking a significant 47% increase from the same period last year [3] CFO Transition - Tycho Peterson, the current CFO, will be leaving the company, and Kyle Piskel, who has been with Adaptive for 8 years, will take over as the new CFO [4][5] - Kyle Piskel has previously served as the Interim CFO and brings over 15 years of financial expertise to the role [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (St ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Conference Call February 14, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Dan Brennan - TD Cowen David Westenberg - Piper Sandler Mark Massaro - BTIG Tejas Savant - Morgan Stanley Andrew Brackmann - William Blair Sung J ...